2021-11-03

Department of Gynecology, Guigang Maternal and Child Health Care Hospital, Guigang, China.; Department of Neurosurgery, Guigang City People's Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Guigang, China.; Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Guilin, China.; Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Guilin, China.; Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Guilin, China.; Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.; Laboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Guilin, China.; Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.

BACKGROUND: Clinically, evidence shows that uterine corpus endometrial carcinoma (UCEC) patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have a higher death-rate. However, current anti-UCEC/coronavirus disease 2019 (COVID-19) treatment is lacking. Plumbagin (PLB), a pharmacologically active alkaloid, is an emerging anti-cancer inhibitor. Accordingly, the current report was designed to identify and characterize the anti-UCEC function and mechanism of PLB in the treatment of patients infected with SARS-CoV-2 via integrated in silico analysis. METHODS: The clinical analyses of UCEC and COVID-19 in patients were conducted using online-accessible tools. Meanwhile, in silico methods including network pharmacology and biological molecular docking aimed to screen and characterize the anti-UCEC/COVID-19 functions, bio targets, and mechanisms of the action of PLB. RESULTS: The bioinformatics data uncovered the clinical characteristics of UCEC patients

2021-04-13

Guilin Medical University.; Guilin Medical University.; Guilin Medical University.; Guilin Medical University.; Guilin Medical University.; Guilin Medical University.

OBJECTIVE: Coronavirus disease 2019 (COVID-19) is a fatal and fast-spreading viral infection. To date, the number of COVID-19 patients worldwide has crossed over six million with over three hundred and seventy thousand deaths (according to the data from World Health Organization; updated on 2 June 2020). Although COVID-19 can be rapidly diagnosed, efficient clinical treatment of COVID-19 remains unavailable, resulting in high fatality. Some clinical trials have identified vitamin C (VC) as a potent compound pneumonia management. In addition, glycyrrhizic acid (GA) is clinically as an anti-inflammatory medicine against pneumonia-induced inflammatory stress. We hypothesized that the combination of VC and GA is a potential option for treating COVID-19. METHODS: The aim of this study was to determine pharmacological targets and molecular mechanisms of VC + GA treatment for COVID-19, using bioinformational network pharmacology. RESULTS: We uncovered optimal targets, biological processes

2021-04-13

Gyuilin Medical University.; Gyuilin Medical University.; Gyuilin Medical University.; Gyuilin Medical University.; Gyuilin Medical University.; Gyuilin Medical University.

OBJECTIVES: Patients with colorectal cancer (CRC) may be susceptible to the coronavirus disease-2019 (COVID-19). However, anti-CRC/COVID-19 treatment options are currently unavailable. Since niacin is a vitamin with cytoprotective and anti-inflammatory functions, this study aimed to evaluate the possible functional roles and underlying mechanisms of action of niacin as an anti-COVID-19 and -CRC therapy. INTERVENTIONS: We used a series of network pharmacology-based and computational analyses to understand and characterize the binding capacity, biological functions, pharmacological targets and therapeutic mechanisms of niacin in CRC/COVID-19. MEASUREMENTS AND MAIN RESULTS: We revealed the clinical characteristics of CRC patients and COVID-19 patients, including predisposing genes, survival rate and prognosis. Moreover, the results of molecular docking analysis indicated that niacin exerted effective binding capacity in COVID-19. Further, we disclosed the targets, biological functions

2021-02-25

Department of Neurology (Area Two), Guigang City People's Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Guigang, China.; The Center for Data Science in Health and Medicine, Business School, Qingdao University, Qingdao, China.; Department of Pharmacy, The Second People's Hospital of Nanning City, The Third Affiliated Hospital of Guangxi Medical University, Nanning, China.; Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.; Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.; Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.; Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.

The present study aimed to uncover the pharmacological function and underlying mechanism of puerarin as a potential treatment for COVID-19, using an in silico methodology, including network pharmacology and molecular docking. The pivotal targets of puerarin to treat COVID-19 were identified and included the epidermal growth factor receptor (EGFR), tumour necrosis factor (TNF), tumour protein p53 (TP53), caspase 3 (CASP3), RELA proto-oncogene (RELA), Fos proto-oncogene (FOS), caspase 8 (CASP8), prostaglandin-endoperoxide synthase 2 (PTGS2), interleukin 2 (IL2), protein kinase CB (PRKCB), B cell lymphoma/leukaemia gene-2 (BCL2), protein kinase CA (PRKCA), nitric oxide synthase 3 (NOS3) and peroxisome proliferator-activated receptor gamma (PPARG). Functionally, the anti-COVID-19 action of puerarin was associated with the suppression of oxidative stress and inflammatory cascades, and cell apoptosis. The signalling pathways of puerarin to treat COVID-19 included modulation of the pathways

2021-08-15

Department of Epidemiology, School of Public Health, Zhengzhou University, No. 100 of Science Avenue, Zhengzhou, 450001, China.; Department of Epidemiology, School of Public Health, Zhengzhou University, No. 100 of Science Avenue, Zhengzhou, 450001, China.; Department of Epidemiology, School of Public Health, Zhengzhou University, No. 100 of Science Avenue, Zhengzhou, 450001, China.; Department of Epidemiology, School of Public Health, Zhengzhou University, No. 100 of Science Avenue, Zhengzhou, 450001, China.; Department of Epidemiology, School of Public Health, Zhengzhou University, No. 100 of Science Avenue, Zhengzhou, 450001, China.; Department of Epidemiology, School of Public Health, Zhengzhou University, No. 100 of Science Avenue, Zhengzhou, 450001, China.; Department of Toxicology, Henan Center for Disease Control and Prevention, Zhengzhou, 450016, China.; Department of Epidemiology, School of Public Health, Zhengzhou University, No. 100 of Science Avenue, Zhengzhou, 450001, China. yhy@zzu.edu.cn.

BACKGROUND: Cardiovascular disease (CVD), one of the most common comorbidities of coronavirus disease 2019 (COVID-19), has been suspected to be associated with adverse outcomes in COVID-19 patients, but their correlation remains controversial. METHOD: This is a quantitative meta-analysis on the basis of adjusted effect estimates. PubMed, Web of Science, MedRxiv, Scopus, Elsevier ScienceDirect, Cochrane Library and EMBASE were searched comprehensively to obtain a complete data source up to January 7, 2021. Pooled effects (hazard ratio (HR), odds ratio (OR)) and the 95% confidence intervals (CIs) were estimated to evaluate the risk of the adverse outcomes in COVID-19 patients with CVD. Heterogeneity was assessed by Cochran's Q-statistic, I(2)test, and meta-regression. In addition, we also provided the prediction interval, which was helpful for assessing whether the variation across studies was clinically significant. The robustness of the results was evaluated by sensitivity analysis.

2021-03-08

Department of Respiratory and Critical Care Medicine, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing, China.; Department of Respiratory and Critical Care Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, China.; Department of Orthopaedics, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.; Department of Health Management Center, Shenzhen Hospital, Southern Medical University, Shenzhen, China.; Department of Respiratory and Critical Care Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, China.; Department of Respiratory and Critical Care Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, China.; Department of Nephrology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.; Department of Respiratory and Critical Care Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, China.; Department of Respiratory and Critical Care Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, China.; Department of Radiology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.; Department of Respiratory and Critical Care Medicine, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing, China.

This study investigates the clinical and imaging characteristics of coronavirus disease 2019 (COVID-19) patients with false-negative nucleic acids. Mild-to-moderate COVID-19 patients, including 19 cases of nucleic acid false-negative patients and 31 cases of nucleic acid positive patients, were enrolled. Their epidemiological, clinical, and laboratory examination data and imaging characteristics were analyzed. Risk factors for false negatives were discussed. Compared with the nucleic acid positive group, the false-negative group had less epidemiological exposure (52.6% vs 83.9%; P  = .025), less chest discomfort (5.3% vs 32.3%; P  = .035), and faster recovery (10 [8, 13] vs 15 [11, 18.5] days; P  = .005). The number of involved lung lobes was (2 [1, 2.5] vs 3 [2, 4] days; P  = .004), and the lung damage severity score was (3 [2.5, 4.5] vs 5 [4, 9] days; P  = .007), which was lighter in the nucleic acid false-negative group. Thus, the absence of epidemiological exposure may be a

2021-02-21

Department of Emergency Medicine.; Department of Emergency Medicine.; Department of Emergency Medicine.; Department of Emergency Medicine.; Department of Emergency Medicine.; Department of Emergency Medicine.; Department of Emergency Medicine.; Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.

Our study aims to summarize the clinical characteristics of patients with severe or critically ill coronavirus disease 2019 (COVID-19).Five databases were electronically searched to collect studies describing clinical characteristics of severe or critically ill COVID-19 patients and published between January 1, 2020 and April 12, 2020. Three reviewers independently collected the literature, extracted the required data, and assessed the risk of publication bias of the included studies before including the studies in the meta-analysis.A total of 40 studies involving 2459 patients with severe or critically ill COVID-19 patients were included. Meta-analysis showed that a greater proportion of severe or critically COVID-19 patients were male (62.3%), and the 2 main clinical symptoms were fever (87.4%) and cough (66.3%). Other common clinical symptoms included dyspnea (45.3%), chest tightness (37.4%), fatigue (36.6%), and expectoration (31.9%). Minor symptoms included myalgia (19.5%),

2021-07-21

Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.; Antigen Discovery, Incorporated, Irvine, California, USA.; Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.; Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.; Antigen Discovery, Incorporated, Irvine, California, USA.; Antigen Discovery, Incorporated, Irvine, California, USA.; Antigen Discovery, Incorporated, Irvine, California, USA.; Antigen Discovery, Incorporated, Irvine, California, USA.; Antigen Discovery, Incorporated, Irvine, California, USA.; Antigen Discovery, Incorporated, Irvine, California, USA.; Antigen Discovery, Incorporated, Irvine, California, USA.; Antigen Discovery, Incorporated, Irvine, California, USA.; Antigen Discovery, Incorporated, Irvine, California, USA.; Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.; Department of Microbiology, Immunology and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia, USA.; Department of Pathology, University of Virginia Health System, Charlottesville, Virginia, USA.; Antigen Discovery, Incorporated, Irvine, California, USA.; Center for Virus Research, University of California, Irvine, Irvine, California, USA.

We sought to discover links between antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and patient clinical variables, cytokine profiles, and antibodies to endemic coronaviruses. Serum samples from 30 patients of younger (26 to 39 years) and older (69 to 83 years) age groups and with varying clinical severities ranging from outpatient to mechanically ventilated were collected and used to probe a novel multi-coronavirus protein microarray. This microarray contained variable-length overlapping fragments of SARS-CoV-2 spike (S), envelope (E), membrane (M), nucleocapsid (N), and open reading frame (ORF) proteins created through in vitro transcription and translation (IVTT). The array also contained SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), human coronavirus OC43 (HCoV-OC43), and HCoV-NL63 proteins. IgG antibody responses to specific epitopes within the S1 protein region spanning amino acids (aa) 500 to 650 and within the N protein

2021-07-07

Center for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing 100191, China.; School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.; State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.; Center for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing 100191, China.; School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.; State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.; Center for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing 100191, China.; Center for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing 100191, China.; State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.; State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.; State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.; State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.; Center for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing 100191, China.; School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.; Peking University First Hospital, Beijing 100034, China.; Peking-Tsinghua Center for Life Sciences, Beijing 100871, China.; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100069, China.; State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

The COVID-19 pandemic has become a worldwide health crisis. So far, most studies have focused on the epidemiology and pathogenesis of this infectious disease. Little attention has been given to the disease sequelae in patients recovering from COVID-19, and nothing is known about the mechanisms underlying these sequelae. Herein, we profiled the serum proteome of a cohort of COVID-19 patients in the disease onset and recovery stages. Based on the close integration of our proteomic analysis with clinical data, we propose that COVID-19 is associated with prolonged disorders in cholesterol metabolism and myocardium, even in the recovery stage. We identify potential biomarkers for these disorders. Moreover, severely affected patients presented more serious disturbances in these pathways. Our findings potentially support clinical decision-making to improve the prognosis and treatment of patients.

2020-04-06

grid.49470.3e0000 0001 2331 6153Global Health Institute, Wuhan University, Wuhan,; China grid.49470.3e0000 0001 2331 6153Global Health Institute, Wuhan University, Wuhan,; China grid.8991.90000 0004 0425 469XDepartment of Global Health and Development, London; School of Hygiene and Tropical Medicine, London, UK grid.448631.cGlobal Health Research Center, Duke Kunshan University, Kunshan,; China grid.8547.e0000 0001 0125 2443School of Public Health, Fudan University,; Shanghai, China Consultant in Global Health, London, UK; grid.49470.3e0000 0001 2331 6153Global Health Institute, Wuhan University, Wuhan,; China grid.256607.00000 0004 1798 2653School of Public Health, Guangxi Medical; University, Guangxi, China grid.49470.3e0000 0001 2331 6153Global Health Institute, Wuhan University, Wuhan,; China grid.411971.b0000 0000 9558 1426Global Health Research Center, Dalian Medical; University, Dalian, China grid.12981.330000 0001 2360 039XSchool of Public Health, Sun Yat-sen University, ; Guangzhou, China grid.49470.3e0000 0001 2331 6153Global Health Institute, Wuhan University, Wuhan,; China grid.49470.3e0000 0001 2331 6153Global Health Institute, Wuhan University, Wuhan,; China grid.49470.3e0000 0001 2331 6153Global Health Institute, Wuhan University, Wuhan,; China grid.49470.3e0000 0001 2331 6153School of Health Sciences, Wuhan University,; Wuhan, China grid.49470.3e0000 0001 2331 6153School of Health Sciences, Wuhan University,; Wuhan, China

The call for “Working Together to Build a Community of Shared Future for Mankind” requires us to improve people’s health across the globe, while global health development entails a satisfactory answer to a fundamental question: “What is global health?” To promote research, teaching, policymaking, and practice in global health, we summarize the main points on the definition of global health from the Editorial Board Meeting of Global Health Research and Policy, convened in July 2019 in Wuhan, China. The meeting functioned as a platform for free brainstorming, in-depth discussion, and post-meeting synthesizing. Through the meeting, we have reached a consensus that global health can be considered as a general guiding principle, an organizing framework for thinking and action, a new branch of sciences and specialized discipline in the large family of public health and medicine. The word “global” in global health can be subjective or